Copyright © 2026 Knight Sac Media. All rights reserved.https://www.siliconinvestor.com/subject.aspx?subjectid=60155MCap $73 Million / Cash $35 Million / NDA submission for BIG drug this or next Q / Another 3 Drugs in Phase 3 = One of the CHEAPEST biotech in the entire sector a potential 10 Bagger here guys .GL Scynexis (SCYX) Market Cap $73 Million Cash $35 Million Price $7.40 Shares Out 9.9 Million Presentation d1io3yog0oux5.cloudfront.net Scynexis' lead drug scores in vaginal yeast infection trial endpts.com Ibrexafungerp,if approved, could end up as the only oral alternative to fluconazole approved for acute VVC infections, although Mycovia is testing another therapy, VT-1161, for patients with recurrent VVC, Needham’s Alan Carr wrote in a note, adding that he expects ibrexafungerp to launch in 2021. “Our data suggest 15% of pts return to their physician because existing treatments are inadequate…physician interest in a new drug is high and we estimate even modest (25%) penetration of the second-line setting generates peak sales (for ibrexafungerp) of over $450M.” [graphic] [graphic]https://www.siliconinvestor.com/images/Logo380x132.pnghttps://www.siliconinvestor.com/subject.aspx?subjectid=6015538013210BioHerohttps://www.siliconinvestor.com/readmsg.aspx?msgid=328489307/23/2020 12:36:30 PM